Search

Objectives: In this study, we determined the incidence and persistence of human papillomavirus (HPV) strains and of squamous intraepithelial lesions (SIL) or worse cytology in 237 HIV‐positive and HIV‐negative Rwandan women and whether the interleukin (IL)‐28B single nucleotide polymorphism (SNP) at rs12979860 correlated with susceptibility to and persistence of HPV infection. Methods: Cervical samples were collected at baseline and after 9, 18 and 24 months for a 40‐HPV DNA screening test and a ThinPrep Pap test. Genotyping of the IL‐28B SNP rs12979860 was performed using real‐time polymerase chain reaction (PCR). Results: Chronic high‐risk (HR) HPV infections occurred in 56% of HIV‐positive women, while no HIV‐negative women developed HPV chronicity. High‐grade SIL (HSIL) or cancer was diagnosed in 38% of HIV‐positive women with persistent HR‐HPV infections. HIV and HR‐HPV positivity at baseline were factors associated with an increased risk of HPV persistence. Additionally, HR‐HPV positivity at baseline was associated with an increased risk of developing HSIL or worse cytology. The unfavourable T/x genotype at rs12979860 is common among Africans, and women with this genotype were found to be more commonly infected with HPV. Conclusions: HPV screening in Rwanda may help to identify women at risk of developing cervical cancer and polymorphism in IL‐28B may be associated with risk of contracting  HPV infection. [ABSTRACT FROM AUTHOR]

Objectives: Cervical cancer is the major cause of death from cancer in Africa. We wanted to assess the prevalence of human papillomavirus (HPV) infections and associated risk factors and to determine whether HPV testing could serve as a screening method for squamous intraepithelial lesions (SILs) in Rwanda. We also wanted to obtain a broader understanding of the underlying risk factors for the establishment of HPV infection in Rwanda. Methods: A total of 206 HIV‐positive women, 172 HIV‐negative women and 22 women with unknown HIV status were recruited at the University Teaching Hospitals of Kigali (UTHK) and of Butare (UTHB) in Rwanda. Participants underwent an interview, cervical sampling for a Thinprep Pap test and a screening test analysing 37 HPV strains. Results: Only 27% of HIV‐positive women and 7% of HIV‐negative women had been screened for cervical cancer before. HPV16 and HPV52 were the most common HPV strains. HIV‐positive women were more commonly infected with high‐risk (HR) HPV and multitype HPV than HIV‐negative women. The sensitivity was 78% and the specificity 87% to detect high‐grade SIL (HSIL) with HPV screening. Among HIV‐negative women, being divorced was positively associated with HR‐HPV infection, while hepatitis B, Trichomonas vaginalis infection and HR‐HPV infection were factors positively associated with SILs. Ever having had gonorrhoea was positively associated with HR‐HPV infection among HIV‐positive women. HR‐HPV infection and the number of live births were positively associated with SILs. Conclusions: The currently used quadrivalent vaccine may be insufficient to give satisfactory HPV coverage in Rwanda. HPV Screening may be effective to identify women at risk of developing cervical cancer, particularly if provided to high‐risk patients. [ABSTRACT FROM AUTHOR]